Aligos Therapeutics’ (ALGS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $75.00 price objective on the stock.

Aligos Therapeutics Stock Performance

Aligos Therapeutics stock opened at $7.21 on Wednesday. The company’s fifty day moving average price is $10.75 and its 200 day moving average price is $13.69. Aligos Therapeutics has a 1 year low of $6.76 and a 1 year high of $30.00. The stock has a market capitalization of $563.17 million, a P/E ratio of -5.63 and a beta of 2.16.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The firm had revenue of $1.06 million for the quarter. During the same period in the prior year, the business posted ($10.75) EPS. Sell-side analysts predict that Aligos Therapeutics will post -8.2 EPS for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC lifted its holdings in Aligos Therapeutics by 17.6% in the 1st quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock valued at $644,000 after purchasing an additional 98,628 shares in the last quarter. Opaleye Management Inc. lifted its holdings in Aligos Therapeutics by 25.7% in the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after purchasing an additional 333,000 shares in the last quarter. Finally, Armistice Capital LLC lifted its holdings in Aligos Therapeutics by 5.3% in the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares in the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).